US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US8409861B2
(en)
*
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
US10689609B2
(en)
|
2012-03-15 |
2020-06-23 |
Flodesign Sonics, Inc. |
Acoustic bioreactor processes
|
US9745548B2
(en)
|
2012-03-15 |
2017-08-29 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
US10322949B2
(en)
|
2012-03-15 |
2019-06-18 |
Flodesign Sonics, Inc. |
Transducer and reflector configurations for an acoustophoretic device
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
US9752113B2
(en)
|
2012-03-15 |
2017-09-05 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
US10737953B2
(en)
|
2012-04-20 |
2020-08-11 |
Flodesign Sonics, Inc. |
Acoustophoretic method for use in bioreactors
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US9745569B2
(en)
|
2013-09-13 |
2017-08-29 |
Flodesign Sonics, Inc. |
System for generating high concentration factors for low cell density suspensions
|
LT3066201T
(lt)
|
2013-11-07 |
2018-08-10 |
Editas Medicine, Inc. |
Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
EP3092049A1
(en)
|
2014-01-08 |
2016-11-16 |
Flodesign Sonics Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
ES2782125T3
(es)
|
2014-03-11 |
2020-09-10 |
Cellectis |
Método para generar linfocitos T compatibles para trasplante alogénico
|
KR20230152175A
(ko)
*
|
2014-04-18 |
2023-11-02 |
에디타스 메디신, 인코포레이티드 |
암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
|
WO2015188228A1
(en)
*
|
2014-06-10 |
2015-12-17 |
Monash University |
Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
|
US9744483B2
(en)
|
2014-07-02 |
2017-08-29 |
Flodesign Sonics, Inc. |
Large scale acoustic separation device
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
EP3215166B1
(en)
*
|
2014-10-31 |
2024-04-24 |
The Trustees of the University of Pennsylvania |
Altering gene expression in car-t cells and uses thereof
|
EP3245286A4
(en)
*
|
2015-01-17 |
2018-07-11 |
Zhejiang University |
Modified cells evoking reduced immunogenic responses
|
BR112017015453A2
(pt)
|
2015-01-26 |
2018-01-23 |
Cellectis |
células imunes modificadas knockout para receptor de células t, dotadas de receptores quiméricos de antígeno, de ligação a cd123 para o tratamento de linfoma mieloide agudo recorrente/refratário ou neoplasia blástica de células dendríticas plasmacitoides
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
US11420136B2
(en)
|
2016-10-19 |
2022-08-23 |
Flodesign Sonics, Inc. |
Affinity cell extraction by acoustics
|
EP4043556B1
(en)
*
|
2015-06-30 |
2024-02-07 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
IL295616A
(en)
|
2015-07-31 |
2022-10-01 |
Us Health |
Adapted cells and treatment methods
|
JP2018522907A
(ja)
*
|
2015-08-11 |
2018-08-16 |
セレクティスCellectis |
Cd38抗原を標的とするためおよびcd38遺伝子を不活化するために操作された、免疫療法用の細胞
|
WO2017049266A2
(en)
*
|
2015-09-18 |
2017-03-23 |
The Regents Of The University Of California |
Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
|
EP4108255A1
(en)
|
2015-10-05 |
2022-12-28 |
Precision Biosciences, Inc. |
Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
|
EP3940070A1
(en)
*
|
2015-10-05 |
2022-01-19 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
WO2017059557A1
(en)
*
|
2015-10-09 |
2017-04-13 |
Peking University |
Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use
|
EP3365357B1
(en)
|
2015-10-23 |
2024-02-14 |
President and Fellows of Harvard College |
Evolved cas9 proteins for gene editing
|
US20180362975A1
(en)
*
|
2015-12-04 |
2018-12-20 |
Novartis Ag |
Compositions and methods for immunooncology
|
AU2016369490C1
(en)
*
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
CN108699132B
(zh)
*
|
2015-12-18 |
2023-08-11 |
桑格摩生物治疗股份有限公司 |
Mhc细胞受体的靶向破坏
|
EP3394253B1
(en)
*
|
2015-12-23 |
2021-09-01 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
|
AU2017226172B9
(en)
*
|
2016-03-04 |
2023-08-24 |
Editas Medicine, Inc. |
CRISPR/Cpf1-related methods, compositions and components for cancer immunotherapy
|
WO2017178586A1
(en)
|
2016-04-15 |
2017-10-19 |
Cellectis |
A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
|
EP3429633B1
(en)
|
2016-04-15 |
2021-02-24 |
Cellectis |
A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
WO2018018958A1
(en)
|
2016-04-22 |
2018-02-01 |
Carsgen Therapeutics Co., Ltd. |
Compositions and methods of cellular immunotherapy
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
CA2937157A1
(en)
|
2016-07-25 |
2018-01-25 |
Ucl Business Plc |
Protein-based t-cell receptor knockdown
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
AU2017306676B2
(en)
|
2016-08-03 |
2024-02-22 |
President And Fellows Of Harvard College |
Adenosine nucleobase editors and uses thereof
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
MX2019003768A
(es)
|
2016-10-03 |
2019-06-24 |
Juno Therapeutics Inc |
Moleculas de enlace especificas de hpv.
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
WO2018075664A1
(en)
|
2016-10-18 |
2018-04-26 |
Regents Of The University Of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
JP7236380B2
(ja)
*
|
2016-10-19 |
2023-03-09 |
セレクティス |
治療に適したtalエフェクターヌクレアーゼ(talen)改変同種異系細胞
|
WO2018073393A2
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
US20210137978A1
(en)
*
|
2017-01-10 |
2021-05-13 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
CN107058230B
(zh)
*
|
2017-01-20 |
2020-03-24 |
山东兴瑞生物科技有限公司 |
一种沉默t细胞抗原受体的t淋巴细胞的制备方法
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
CA3054621A1
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
IL306092A
(en)
|
2017-03-23 |
2023-11-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
WO2018178378A1
(en)
|
2017-03-31 |
2018-10-04 |
Cellectis Sa |
New universal chimeric antigen receptor t cells specific for cd22
|
WO2018191490A1
(en)
*
|
2017-04-13 |
2018-10-18 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
|
JP7170666B2
(ja)
*
|
2017-05-08 |
2022-11-14 |
プレシジョン バイオサイエンシズ,インク. |
操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
EP3621981A2
(en)
|
2017-05-12 |
2020-03-18 |
CRISPR Therapeutics AG |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
CN111201438A
(zh)
*
|
2017-06-02 |
2020-05-26 |
朱诺治疗学股份有限公司 |
与和细胞疗法相关的毒性有关的制品和方法
|
EP3638775A1
(en)
*
|
2017-06-13 |
2020-04-22 |
Fate Therapeutics, Inc. |
Compositions and methods for inducing myeloid suppressive cells and use thereof
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
AU2018283310A1
(en)
*
|
2017-06-16 |
2020-01-02 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
WO2019006330A1
(en)
*
|
2017-06-30 |
2019-01-03 |
Indiana University Research And Technology Corporation |
COMPOSITIONS AND METHODS FOR DETECTING REACTIVITY TO ALS
|
WO2019002633A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
EP3645038A1
(en)
|
2017-06-30 |
2020-05-06 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
CN111278980A
(zh)
*
|
2017-07-14 |
2020-06-12 |
苏州克睿基因生物科技有限公司 |
一种基因编辑系统及基因编辑的方法
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
EP3680338A4
(en)
*
|
2017-09-08 |
2021-06-02 |
Carsgen Therapeutics Co., Ltd. |
GENETICALLY MODIFIED LYMPHOCYTE T AND ITS APPLICATION
|
EP4215543A3
(en)
|
2017-10-03 |
2023-10-11 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
JP2021502056A
(ja)
*
|
2017-10-05 |
2021-01-28 |
ナントセル,インコーポレイテッド |
脂質ベースの抗原及びnk細胞上のt細胞受容体
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
EP3684919A1
(en)
*
|
2017-10-19 |
2020-07-29 |
Cellectis |
Targeted gene integration of nk inhibitors genes for improved immune cells therapy
|
CN109694854B
(zh)
*
|
2017-10-20 |
2023-11-21 |
亘喜生物科技(上海)有限公司 |
通用型嵌合抗原受体t细胞制备技术
|
CN107723275B
(zh)
*
|
2017-10-20 |
2020-09-04 |
重庆精准生物技术有限公司 |
通用型car-t细胞及其制备方法和应用
|
CN109750035B
(zh)
*
|
2017-11-02 |
2020-06-05 |
上海邦耀生物科技有限公司 |
靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA
|
WO2019097083A1
(en)
*
|
2017-11-20 |
2019-05-23 |
Tessa Therapeutics Pte. Ltd. |
Modified k562 cell
|
JP2021505208A
(ja)
*
|
2017-12-05 |
2021-02-18 |
セリアド エス.アー.Celyad S.A. |
養子細胞療法用細胞の持続性を向上するための組成物および方法
|
AU2018386010A1
(en)
*
|
2017-12-13 |
2020-05-14 |
Janssen Biotech, Inc. |
Immortalized car-T cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
|
BR112020009889A2
(pt)
|
2017-12-14 |
2020-11-03 |
Flodesign Sonics, Inc. |
acionador e controlador de transdutor acústico
|
US11227325B1
(en)
|
2017-12-18 |
2022-01-18 |
Wells Fargo Bank, N.A. |
Event-based automatic transaction system
|
EP3757133A4
(en)
*
|
2018-02-11 |
2021-12-01 |
Jiangsu Hengrui Medicine Co., Ltd. |
ISOLATED CHIMERIC ANTIGEN RECEPTOR, THIS MODIFIED T-CELL CONTAINED AND USES
|
JP7385281B2
(ja)
*
|
2018-02-16 |
2023-11-22 |
国立大学法人京都大学 |
低抗原性細胞の製造方法
|
US20210040449A1
(en)
*
|
2018-02-16 |
2021-02-11 |
Kite Pharma, Inc. |
Modified pluripotent stem cells and methods of making and use
|
BR112020020245A2
(pt)
|
2018-04-05 |
2021-04-06 |
Editas Medicine, Inc. |
Métodos de produzir células expressando um receptor recombinante e composições relacionadas
|
RU2020136054A
(ru)
|
2018-04-05 |
2022-05-06 |
Джуно Терапьютикс, Инк. |
Т-клетки, экспрессирующие рекомбинантный рецептор, соответствующие полинуклеотиды и способы
|
EP3773908A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
IL304025A
(en)
|
2018-04-12 |
2023-08-01 |
Prec Biosciences Inc |
Optimized engineered nucleases with specificity for the human T cell receptor alpha constant region gene
|
WO2019204664A2
(en)
*
|
2018-04-19 |
2019-10-24 |
Apdn (B.V.I), Inc. |
Engineered lymphocyte compositions, methods and systems
|
EP3781590A1
(en)
|
2018-04-20 |
2021-02-24 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
|
BR112020021660A2
(pt)
|
2018-04-27 |
2021-02-02 |
Iovance Biotherapeutics, Inc. |
métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, composição de criopreservação
|
BR112020021856A2
(pt)
*
|
2018-04-27 |
2021-02-23 |
Crispr Therapeutics Ag |
métodos e composições de depleção de célula t citotóxica
|
EP3790629A1
(en)
|
2018-05-11 |
2021-03-17 |
CRISPR Therapeutics AG |
Methods and compositions for treating cancer
|
KR20210065141A
(ko)
*
|
2018-09-21 |
2021-06-03 |
카파 테라퓨틱스 리미티드 |
CRISPR/Cas 시스템을 기반으로 한 세포의 유전자 편집 방법
|
CN109266618B
(zh)
*
|
2018-10-18 |
2021-04-23 |
赛元生物科技(杭州)有限公司 |
能够靶向肿瘤细胞的巨噬细胞及其制备方法
|
SG11202103832SA
(en)
*
|
2018-11-07 |
2021-05-28 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
CN113015750A
(zh)
*
|
2018-11-07 |
2021-06-22 |
克里斯珀医疗股份公司 |
抗liv1免疫细胞癌症疗法
|
CN111349606A
(zh)
*
|
2018-12-20 |
2020-06-30 |
上海恒润达生生物科技有限公司 |
P60抑制剂与cart细胞联合应用
|
AU2020211564A1
(en)
*
|
2019-01-07 |
2021-07-22 |
The Regents Of The University Of California |
Synthetic molecular feedback circuits and methods of using the same
|
CN109706121A
(zh)
*
|
2019-01-25 |
2019-05-03 |
苏州茂行生物科技有限公司 |
一种基于碱基编辑的通用型car-t细胞及其制备方法和应用
|
EP3924480A4
(en)
*
|
2019-02-13 |
2023-08-02 |
Beam Therapeutics, Inc. |
MODIFIED IMMUNE CELLS HAVING ADENOSINE DEAMINASE BASE EDITORS TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE
|
WO2020172571A1
(en)
*
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
WO2020180882A1
(en)
|
2019-03-05 |
2020-09-10 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
JP2022526908A
(ja)
|
2019-03-19 |
2022-05-27 |
ザ ブロード インスティテュート,インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
WO2020206248A1
(en)
|
2019-04-03 |
2020-10-08 |
Precision Biosciences, Inc. |
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
CN114174325A
(zh)
*
|
2019-06-04 |
2022-03-11 |
恩卡尔塔公司 |
用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
|
TW202115245A
(zh)
*
|
2019-06-27 |
2021-04-16 |
丹麥商諾佛 儂迪克股份有限公司 |
安全免疫隱形細胞
|
KR20220028090A
(ko)
*
|
2019-06-28 |
2022-03-08 |
카파 테라퓨틱스 리미티드 |
이식 반응에 저항하는 세포 및 방법
|
JP2024500254A
(ja)
*
|
2019-08-29 |
2024-01-09 |
クレージュ メディカル カンパニー,リミテッド |
移植拒絶反応に抵抗する細胞及び方法
|
CA3150233A1
(en)
*
|
2019-09-05 |
2021-03-11 |
Alireza Rezania |
UNIVERSAL DONOR CELLS
|
JP2022547505A
(ja)
*
|
2019-09-05 |
2022-11-14 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
ユニバーサルドナー細胞
|
CA3155727A1
(en)
|
2019-10-25 |
2021-04-29 |
Cecile Chartier-Courtaud |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
CN114728021A
(zh)
*
|
2019-11-05 |
2022-07-08 |
隆萨沃克斯维尔股份有限公司 |
同种异体t细胞和其产生方法
|
JPWO2021106832A1
(ru)
*
|
2019-11-25 |
2021-06-03 |
|
|
EP4081537A1
(en)
|
2019-12-23 |
2022-11-02 |
Cellectis |
New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
|
WO2021150078A1
(ko)
*
|
2020-01-23 |
2021-07-29 |
주식회사 강스템바이오텍 |
Off-the-shelf 줄기세포 및 면역세포, 이를 포함하는 약학적 조성물
|
WO2021202581A1
(en)
*
|
2020-03-30 |
2021-10-07 |
WUGEN, Inc. |
Engineered immune cells for adoptive cell therapy
|
EP4139458A1
(en)
*
|
2020-04-23 |
2023-03-01 |
AZTherapies, Inc. |
Cellular ablation of hla-class i mhc
|
AU2021267940A1
(en)
|
2020-05-08 |
2022-12-08 |
President And Fellows Of Harvard College |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
US20230228739A1
(en)
|
2020-07-03 |
2023-07-20 |
Cellectis S.A. |
Method for determining potency of chimeric antigen receptor expressing immune cells
|
KR20220005208A
(ko)
*
|
2020-07-06 |
2022-01-13 |
주식회사 지씨셀 |
면역원성이 감소된 신규한 이식용 세포
|
WO2022007784A1
(en)
*
|
2020-07-06 |
2022-01-13 |
Nanjing Legend Biotech Co., Ltd. |
Methods of reducing graft rejection of allogeneic cell therapy
|
EP4185616A1
(en)
|
2020-07-24 |
2023-05-31 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
US20230279350A1
(en)
|
2020-07-31 |
2023-09-07 |
Cellectis S.A. |
Dual car-t cells
|
TW202214846A
(zh)
*
|
2020-08-20 |
2022-04-16 |
美商A2生物治療學股份有限公司 |
用於治療egfr陽性癌症之組合物及方法
|
CN114426583B
(zh)
*
|
2020-10-29 |
2023-10-10 |
中国科学技术大学 |
用于急性髓系白血病的细胞疗法的嵌合抗原受体
|
CN114525259A
(zh)
*
|
2020-11-03 |
2022-05-24 |
南京北恒生物科技有限公司 |
靶向cd7的嵌合抗原受体及其用途
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
US11883432B2
(en)
|
2020-12-18 |
2024-01-30 |
Century Therapeutics, Inc. |
Chimeric antigen receptor system with adaptable receptor specificity
|
CN114657137A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向BTLA的shRNA和/或shRNA-miR的多能干细胞或其衍生物
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
US20240117007A1
(en)
|
2021-02-10 |
2024-04-11 |
Cure Genetics Co., Limited |
Proliferation enhancer and use thereof
|
JP2024509853A
(ja)
|
2021-03-03 |
2024-03-05 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞療法およびdgk阻害剤の組合せ
|
CA3212439A1
(en)
|
2021-03-19 |
2022-09-22 |
Michelle SIMPSON-ABELSON |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
EP4313122A1
(en)
|
2021-03-23 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
IL308012A
(en)
|
2021-04-30 |
2023-12-01 |
Cellectis Sa |
Anti-MUC1 for novel chimeric antigen receptors and genetically engineered immune cells for solid tumor immunotherapy
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
EP4341300A1
(en)
|
2021-05-21 |
2024-03-27 |
Cellectis S.A. |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
WO2023004074A2
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
CN117858943A
(zh)
*
|
2021-08-24 |
2024-04-09 |
赛斯尔擎生物技术(上海)有限公司 |
T细胞产品及其用途
|
US20230190809A1
(en)
*
|
2021-09-10 |
2023-06-22 |
Tmunity Therapeutics Inc. |
Alternative generation of allogeneic human t cells
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023151620A1
(zh)
*
|
2022-02-09 |
2023-08-17 |
恺兴生命科技(上海)有限公司 |
用于细胞免疫学的组合物和方法
|
WO2023183434A2
(en)
*
|
2022-03-22 |
2023-09-28 |
Artisan Development Labs, Inc. |
Compositions and methods for generating cells with reduced immunogenicty
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201340A2
(en)
*
|
2022-04-15 |
2023-10-19 |
The General Hospital Corporation |
Compositions and methods for reducing cell therapy immunogenicity
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
CN117004604A
(zh)
*
|
2022-04-28 |
2023-11-07 |
南京北恒生物科技有限公司 |
一种ciita基因被敲除的工程化免疫细胞及其用途
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
EP4282963A1
(en)
|
2022-05-23 |
2023-11-29 |
Eberhard Karls Universität Tübingen, Medizinische Fakultät |
Nucleic acid modified biological cell with expansion-dependent gene expression
|
CN114958768B
(zh)
*
|
2022-06-02 |
2023-03-24 |
健颐生物科技发展(山东)有限公司 |
Fgf10旁分泌通用型人成纤维细胞制剂的制备方法
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|